Journal of Experimental & Clinical Cancer Research

Article	Citations
Positive feedback between lncRNA FLVCR1-AS1 and KLF10 may inhibit pancreatic cancer progression via the PTEN/AKT pathway	445
Chemotherapy-induced PTEN-L secretion promotes the selection of PTEN-deficient tumor cells	352
The DCDC2/ENO1 axis promotes tumor progression and immune evasion in intrahepatic cholangiocarcinoma via activating FGL1-LAG3 checkpoint	285
Retraction Note: TRIM11 overexpression promotes proliferation, migration and invasion of lung cancer cells	230
PABPC1-induced stabilization of IFI27 mRNA promotes angiogenesis and malignant progression in esophageal squamous cell carcinoma through exosomal miRNA-21-5p	215
M2 macrophage-secreted KYNU promotes stemness remodeling and malignant behavior in endometrial cancer via the SOD2-mtROS-ERO1α-UPRER axis	199
Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer	181
CCNY-mediated phosphorylation and TET2-BACH1-driven DNA demethylation activate PRC1 to augment NSCLC progression	168
LncRNA FTO-IT1 promotes glycolysis and progression of hepatocellular carcinoma through modulating FTO-mediated N6-methyladenosine modification on GLUT1 and PKM2	155
The RNA methyltransferase METTL16 enhances cholangiocarcinoma growth through PRDM15-mediated FGFR4 expression	153
CircFOXK2 promotes hepatocellular carcinoma progression and leads to a poor clinical prognosis via regulating the Warburg effect	152
Combination of dual JAK/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer	149
FOXD1-dependent RalA-ANXA2-Src complex promotes CTC formation in breast cancer	148
Fast detection, a precise and sensitive diagnostic agent for breast cancer	145
Retraction Note: Tripartite motif-containing 14 (TRIM14) promotes epithelial-mesenchymal transition via ZEB2 in glioblastoma cells	144
Targeting the HLA-E–NKG2A axis in combination with MS-275 enhances NK cell-based immunotherapy against DMG	143
Targeting homologous recombination deficiency in uterine leiomyosarcoma	141
Ropivacaine as a novel AKT1 specific inhibitor regulates the stemness of breast cancer	140
The neuronal protein Neuroligin 1 promotes colorectal cancer progression by modulating the APC/β-catenin pathway	134
The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma	130
Regulatory role of lncH19 in RAC1 alternative splicing: implication for RAC1B expression in colorectal cancer	127
Super-enhancer-associated TMEM44-AS1 aggravated glioma progression by forming a positive feedback loop with Myc	126
The potential of swine pseudorabies virus attenuated vaccine for oncolytic therapy against malignant tumors	124
Correction: circular RNA circATP9A promotes non-small cell Lung cancer progression by interacting with HuR and by promoting extracellular vesicles-mediated macrophage M2 polarization	113
The RNA-binding protein GRSF1 promotes hepatocarcinogenesis via competitively binding to YY1 mRNA with miR-30e-5p	113

CRISPR-Cas9 knockout screening identifies KIAA1429 as an essential gene in Ewing sarcoma	111
NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer	107
SEC23A confers ER stress resistance in gastric cancer by forming the ER stress-SEC23A-autophagy negative feedback loop	107
MYSM1 inhibits human colorectal cancer tumorigenesis by activating miR-200 family members/CDH1 and blocking PI3K/AKT signaling	104
CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response	102
HIF-1α switches the functionality of TGF-β signaling via changing the partners of smads to drive glucose metabolic reprogramming in non-small cell lung cancer	100
Oridonin promotes endoplasmic reticulum stress via TP53-repressed TCF4 transactivation in colorectal cancer	98
HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway	98
The importance of being CAFs (in cancer resistance to targeted therapies)	96
Cell therapy using ex vivo reprogrammed macrophages enhances antitumor immune responses in melanoma	95
Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade	93
HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation	92
LncRNA MILIP links YBX1 to translational activation of Snai1 and promotes metastasis in clear cell renal cell carcinoma	92
Ref-1 redox activity alters cancer cell metabolism in pancreatic cancer: exploiting this novel finding as a potential target	92
The role of TBK1 in cancer pathogenesis and anticancer immunity	90
Blockade of glutamine-dependent cell survival augments antitumor efficacy of CPI-613 in head and neck cancer	88
EIF4A3-mediated biogenesis of circSTX6 promotes bladder cancer metastasis and cisplatin resistance	88
Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment	87
Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy	87
The RP11-417E7.1/THBS2 signaling pathway promotes colorectal cancer metastasis by activating the Wnt/β-catenin pathway and facilitating exosome-mediated M2 macrophage polarization	87
Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?	87
The reprogramming impact of SMAC-mimetic on glioblastoma stem cells and the immune tumor microenvironment evolution	86
Genome-wide CRISPR screening identifies PHF8 as an effective therapeutic target for KRAS- or BRAF-mutant colorectal cancers	85
Cystine/glutamate antiporter xCT deficiency reduces metastasis without impairing immune system function in breast cancer mouse models	84
Correction: GPR119 agonist enhances gefitinib responsiveness through lactate-mediatedinhibition of autophagy	82
Correction to: Epigenetic mediated zinc finger protein 671 downregulation promotes cell proliferation and tumorigenicity in nasopharyngeal carcinoma by inhibiting cell cycle arrest	81
Correction: LncRNA-mediated DNA methylation: an emerging mechanism in cancer and beyond	77
Correction: Synthetic tetracycline-controllable shRNA targeting long non-coding RNA HOXD-AS1 inhibits the progression of bladder cancer	76
Blockade of αvβ6 and αvβ8 integrins with a chromogranin A-derived peptide inhibits TGFβ activation in tumors and suppresses tumor growth	73
C-Myc-activated long non-coding RNA LINC01050 promotes gastric cancer growth and metastasis by sponging miR-7161-3p to regulate SPZ1 expression	73
Correction: Deliberation concerning the role of M1-type macrophage subset in oral carcinogenesis	72
Plasma-derived extracellular vesicles miR-335–5p as potential diagnostic biomarkers for fusion-positive rhabdomyosarcoma	72
Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop	72
Multiple mechanisms and applications of tertiary lymphoid structures and immune checkpoint blockade	72
WNT11/ROR2 signaling is associated with tumor invasion and poor survival in breast cancer	70
MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis	69
The CD70-CD27 axis in oncology: the new kids on the block	69
Cellular based immunotherapy for primary liver cancer	69
Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth	68
Complement inhibitor CSMD1 modulates epidermal growth factor receptor oncogenic signaling and sensitizes breast cancer cells to chemotherapy	68
Arachidonic acid drives adaptive responses to chemotherapy-induced stress in malignant mesothelioma	66
Alloantigen-activated (AAA) CD4+ T cells reinvigorate host endogenous T cell immunity to eliminate pre-established tumors in mice	66
MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma	66
Tumorigenesis of basal muscle invasive bladder cancer was mediated by PTEN protein degradation resulting from SNHG1 upregulation	66
Emerging frontiers in androgen receptor research for prostate Cancer: insights from the 2nd international androgen receptor Symposium	65
RETRACTED ARTICLE: Long non-coding RNA SLC2A1-AS1 induced by GLI3 promotes aerobic glycolysis and progression in esophageal squamous cell carcinoma by sponging miR-378a-3p to enhance Glut1 expression	65
Correction to: Knockdown of FOXO3a induces epithelial-mesenchymal transition and promotes metastasis of pancreatic ductal adenocarcinoma by activation of the β-catenin/TCF4 pathway through SPRY2	64
The KLF16/MYC feedback loop is a therapeutic target in bladder cancer	63
Mechanisms of neural infiltration-mediated tumor metabolic reprogramming impacting immunotherapy efficacy in non-small cell lung cancer	63
Platform combining statistical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinoma	63

A blood-based liquid biopsy analyzing soluble immune checkpoints and cytokines identifies distinct neuroendocrine tumors	63
Correction to: Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer	63
Epstein-Barr viral product-containing exosomes promote fibrosis and nasopharyngeal carcinoma progression through activation of YAP1/FAPα signaling in fibroblasts	62
Ficolin 3 promotes ferroptosis in HCC by downregulating IR/SREBP axis-mediated MUFA synthesis	61
Connecting the dots: investigating the link between environmental, genetic, and epigenetic influences in metabolomic alterations in oral squamous cell carcinoma	61
LINC00460/miR-186-3p/MYC feedback loop facilitates colorectal cancer immune escape by enhancing CD47 and PD-L1 expressions	61
Correction: Targeting FTO induces colorectal cancer ferroptotic cell death by decreasing SLC7A11/ GPX4 expression	61
Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer	61
Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity	60
METTL3 recruiting M2-type immunosuppressed macrophages by targeting m6A-SNAIL-CXCL2 axis to promote colorectal cancer pulmonary metastasis	60
The follicular lymphoma epigenome regulates its microenvironment	60
PARP1-targeted fluorescence molecular endoscopy as novel tool for early detection of esophageal dysplasia and adenocarcinoma	60
Targeting mTOR and survivin concurrently potentiates radiation therapy in renal cell carcinoma by suppressing DNA damage repair and amplifying mitotic catastrophe	59
Regulation of the Hippo/YAP axis by CXCR7 in the tumorigenesis of gastric cancer	58
TSP50 facilitates breast cancer stem cell-like properties maintenance and epithelial-mesenchymal transition via PI3K p110α mediated activation of AKT signaling pathway	58
Zebrafish xenograft model for studying mechanism and treatment of non-small cell lung cancer brain metastasis	58
C-FOS promotes the formation of neutrophil extracellular traps and the recruitment of neutrophils in lung metastasis of triple-negative breast cancer	57
Exosomal long noncoding RNA MLETA1 promotes tumor progression and metastasis by regulating the miR-186-5p/EGFR and miR-497-5p/IGF1R axes in non-small cell lung cancer	57
Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial	57
Detection and characterization of pancreatic and biliary tract cancers using cell-free DNA fragmentomics	57
PARD3 drives tumorigenesis through activating Sonic Hedgehog signalling in tumour-initiating cells in liver cancer	57
Stanniocalcin 1 promotes metastasis, lipid metabolism and cisplatin chemoresistance via the FOXC2/ITGB6 signaling axis in ovarian cancer	57
Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance	56
Kremen2 drives the progression of non-small cell lung cancer by preventing SOCS3-mediated degradation of EGFR	56
Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer	56
The interplay between noncoding RNA and YAP/TAZ signaling in cancers: molecular functions and mechanisms	55
Harnessing cancer stem cell-derived exosomes to improve cancer therapy	55
XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor	54
The role of the tumor microbe microenvironment in the tumor immune microenvironment: bystander, activator, or inhibitor?	54
Cellular senescence in cancer: clinical detection and prognostic implications	53
The HIF1α-PDGFD-PDGFRα axis controls glioblastoma growth at normoxia/mild-hypoxia and confers sensitivity to targeted therapy by echinomycin	53
Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma	52
Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations	52
Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy	52
PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity	52
RNA m6A demethylase FTO-mediated epigenetic up-regulation of LINC00022 promotes tumorigenesis in esophageal squamous cell carcinoma	51
Circular RNA circATP9A promotes non-small cell lung cancer progression by interacting with HuR and by promoting extracellular vesicles-mediated macrophage M2 polarization	51
Correction to: Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas	50
Correction: Colorectal carcinoma peritoneal metastases‑derived organoids: results and perspective of a model for tailoring hyperthermic intraperitoneal chemotherapy from bench‑to‑bedside	50
Protein homeostasis maintained by HOOK1 levels promotes the tumorigenic and stemness properties of ovarian cancer cells through reticulum stress and autophagy	50
Retraction Note: Integrin-β5, a miR-185-targeted gene, promotes hepatocellular carcinoma tumorigenesis by regulating β-catenin stability	50
Deciphering the nonsense-mediated mRNA decay pathway to identify cancer cell vulnerabilities for effective cancer therapy	50
Retraction Note: LncMAPK6 drives MAPK6 expressionand liver TIC self-renewal	50
Correction: A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia	50
Extracellular vesicles activated cancer-associated fibroblasts promote lung cancer metastasis through mitophagy and mtDNA transfer	49
LncRNA AL139294.1 can be transported by extracellular vesicles to promote the oncogenic behaviour of recipient cells through activation of the Wnt and NF-κB2 pathways in non-small-cell lung cancer	49
Non-canonical activation of MAPK signaling by the lncRNA ASH1L-AS1-encoded microprotein APPLE through inhibition of PP1/PP2A-mediated ERK1/2 dephosphorylation in hepatocellular carcinoma	49
CD70 CAR-T cells empowered by TS-2021 through ex vivo transduction show potent antitumor efficacy against glioblastoma	49
SH3GLB1-related autophagy mediates mitochondrial metabolism to acquire resistance against temozolomide in glioblastoma	48
CHD1L in cancer and beyond: structure, oncogenic functions, and therapeutic potential	48
CRISPR/Cas9: a powerful tool in colorectal cancer research	48
A combination of PD-1 and TIGIT immune checkpoint inhibitors elicits a strong anti-tumour response in mesothelioma	48
Predicting response to immunotherapy in gastric cancer via assessing perineural invasion-mediated inflammation in tumor microenvironment	48
Noncoding RNAs as sensors of tumor microenvironmental stress	48
Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition	47
Novel Pt@PCN-Cu-induced cuproptosis amplifies αPD-L1 immunotherapy in pancreatic ductal adenocarcinoma through mitochondrial HK2-mediated PD-L1 upregulation	47
YTHDC1 is downregulated by the YY1/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathway	47
HDAC6 involves in regulating the lncRNA-microRNA-mRNA network to promote the proliferation of glioblastoma cells	47
Three-dimensional environment sensitizes pancreatic cancer cells to the anti-proliferative effect of budesonide by reprogramming energy metabolism	47
A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle	47
CircZNF215 promotes tumor growth and metastasis through inactivation of the PTEN/AKT pathway in intrahepatic cholangiocarcinoma	47
“Small extracellular vesicles: messengers at the service of breast cancer agenda in the primary and distant microenvironments”	47
HERC5 downregulation in non-small cell lung cancer is associated with altered energy metabolism and metastasis	46
CircRNF10 triggers a positive feedback loop to facilitate progression of glioblastoma via redeploying the ferroptosis defense in GSCs	46
LAMC2 marks a tumor-initiating cell population with an aggressive signature in pancreatic cancer	46
Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy	46
CircLRFN5 inhibits the progression of glioblastoma via PRRX2/GCH1 mediated ferroptosis	46
Different pancreatic cancer microenvironments convert iPSCs into cancer stem cells exhibiting distinct plasticity with altered gene expression of metabolic pathways	46
TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer	46
TRPM7 silencing modulates glucose metabolic reprogramming to inhibit the growth of ovarian cancer by enhancing AMPK activation to promote HIF-1α degradation	46
Retraction Note: TRIM29 facilitates the epithelial‑to-mesenchymal transition and the progression of colorectal cancer via the activation of the Wnt/β-catenin signaling pathway	45
Transcriptomics-based liquid biopsy panel for early non-invasive identification of peritoneal recurrence and micrometastasis in locally advanced gastric cancer	45
Retraction Note: Dual loading miR-218 mimics and Temozolomide using AuCOOH@FA-CS drug delivery system: promising targeted antitumor drug delivery system with sequential release functions	45
Progesterone boosts abiraterone-driven target and NK cell therapies against glioblastoma	45
The crosstalk between immune cells and tumor pyroptosis: advancing cancer immunotherapy strategies	45
Augmented ERO1α upon mTORC1 activation induces ferroptosis resistance and tumor progression via upregulation of SLC7A11	44
TSPAN18 facilitates bone metastasis of prostate cancer by protecting STIM1 from TRIM32-mediated ubiquitination	44
HHLA2 activates c-Met and identifies patients for targeted therapy in hepatocellular carcinoma	44
Chronic stress accelerates glioblastoma progression via DRD2/ERK/β-catenin axis and Dopamine/ERK/TH positive feedback loop	44
HSPA4 upregulation induces immune evasion via ALKBH5/CD58 axis in gastric cancer	44

Correction: MKRN1 promotes colorectal cancer metastasis by activating the TGF-β signalling pathway through SNIP1 protein degradation	44
Antibody drug conjugates: hitting the mark in pancreatic cancer?	44
Isolation and characterization of two newly established thymoma PDXs from two relapses of the same patient: a new tool to investigate thymic malignancies	44
Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States	44
PITX2C increases the stemness features of hepatocellular carcinoma cells by up-regulating key developmental factors in liver progenitor	44
o8G-modified circKIAA1797 promotes lung cancer development by inhibiting cuproptosis	43
The lncRNA HOTAIR: a pleiotropic regulator of epithelial cell plasticity	43
METTL16 promotes glycolytic metabolism reprogramming and colorectal cancer progression	43
Correction: SH3GLB1-related autophagy mediates mitochondrial metabolism to acquire resistance against temozolomide in glioblastoma	42
miR-92a-1-5p enriched prostate cancer extracellular vesicles regulate osteoclast function via MAPK1 and FoxO1	42
Cancer-educated mammary adipose tissue-derived stromal/stem cells in obesity and breast cancer: spatial regulation and function	42
A chimeric antigen receptor tailored to integrate complementary activation signals potentiates the antitumor activity of NK cells	42
HIF-2α/LINC02609/APOL1-mediated lipid storage promotes endoplasmic reticulum homeostasis and regulates tumor progression in clear-cell renal cell carcinoma	41
ZMAT1 acts as a tumor suppressor in pancreatic ductal adenocarcinoma by inducing SIRT3/p53 signaling pathway	41
Oncometabolite D-2HG drives tumor metastasis and protumoral macrophage polarization by targeting FTO/m6A/ANGPTL4/integrin axis in triple-negative breast cancer	41
Emerging roles of circular RNAs in gastric cancer metastasis and drug resistance	41
SMARCA5 interacts with NUP98-NSD1 oncofusion protein and sustains hematopoietic cells transformation	41
PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands	41
Cryoablation-induced neutrophil Ca2+ elevation and NET formation exacerbate immune escape in colorectal cancer liver metastasis	41
CCR8 antagonist suppresses liver cancer progression via turning tumor-infiltrating Tregs into less immunosuppressive phenotype	40
Biopiezoelectric-based nanomaterials; a promising strategy in cancer therapy	40
Reactive oxygen species-inducing titanium peroxide nanoparticles as promising radiosensitizers for eliminating pancreatic cancer stem cells	40
Cancer-associated fibroblasts as a potential novel liquid biopsy marker in cancer patients	40
Long-term exposure to house dust mites accelerates lung cancer development in mice	40
Chemotherapy-triggered changes in stromal compartment drive tumor invasiveness and progression of breast cancer	40
S1PR1 suppresses lung adenocarcinoma progression through p-STAT1/miR-30c-5 p/FOXA1 pathway	40
RETRACTED ARTICLE: N6-methyladenosine modification of circMARK2 enhances cytoplasmic export and stabilizes LIN28B, contributing to the progression of Wilms tumor	39
S100A9+CD14+ monocytes contribute to anti-PD-1 immunotherapy resistance in advanced hepatocellular carcinoma by attenuating T cell-mediated antitumor function	39
Correction: CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer	39
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy	39
Notch1 blockade by a novel, selective anti-Notch1 neutralizing antibody improves immunotherapy efficacy in melanoma by promoting an inflamed TME	39
Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer	39
CIRP promotes the progression of non-small cell lung cancer through activation of Wnt/β-catenin signaling via CTNNB1	38
Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy	38
FOXQ1-mediated SIRT1 upregulation enhances stemness and radio-resistance of colorectal cancer cells and restores intestinal microbiota function by promoting β-catenin nuclear translocation	38
Endoplasmic reticulum-localized circular RNA FAM13B restrains nasopharyngeal carcinoma lymphatic metastasis through downregulating XBP1	38
Correction: albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis	38
Autocrine regulation of tumor cell repopulation by Hsp70-HMGB1 alarmin complex	38
Chlorpromazine induces cytotoxic autophagy in glioblastoma cells via endoplasmic reticulum stress and unfolded protein response	38
High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer	38
IL-33 stimulates the anticancer activities of eosinophils through extracellular vesicle-driven reprogramming of tumor cells	38
LATS1/2 loss promote tumor immune evasion in endometrial cancer through downregulating MHC-I expression	38
RNF31 represses cell progression and immune evasion via YAP/PD-L1 suppression in triple negative breast Cancer	38
Pathogenic mitochondrial DNA variants are associated with response to anti-VEGF therapy in ovarian cancer PDX models	37
Cancer-associated fibroblasts-derived CXCL12 enhances immune escape of bladder cancer through inhibiting P62-mediated autophagic degradation of PDL1	37
Correction: The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma	37
The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability	37
Tumor-associated macrophage-derived exosomes LINC01592 induce the immune escape of esophageal cancer by decreasing MHC-I surface expression	37
Correction: Long non-coding RNA DANCR promotes malignant phenotypes of bladder cancer cells by modulating the miR-149/MSI2 axis as a ceRNA	37
Immunotherapy for glioblastoma: the promise of combination strategies	37
Correction: UFM1 suppresses invasive activities of gastric cancer cells by attenuating the expression of PDK1 through PI3K/AKT signaling	37
MEN1 silencing aggravates tumorigenic potential of AR-independent prostate cancer cells through nuclear translocation and activation of JunD and β-catenin	37
Correction: Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms	36
Correction: TSPAN18 facilitates bone metastasis of prostate cancer by protecting STIM1 from TRIM32-mediated ubiquitination	36
Retraction Note: Transcriptional repression of SOCS3 mediated by IL-6/STAT3 signaling via DNMT1 promotes pancreatic cancer growth and metastasis	36
Dysbiotic microbes and how to find them: a review of microbiome profiling in prostate cancer	36
Retraction Note: Downregulation of lncRNA ZNF582-AS1 due to DNA hypermethylation promotes clear cell renal cell carcinoma growth and metastasis by regulating the N(6)- methyladenosine modification of	36
Targeting the radiation-induced ARv7-mediated circNHS/miR-512-5p/XRCC5 signaling with Quercetin increases prostate cancer radiosensitivity	35
STUB1-mediated K63-linked ubiquitination of UHRF1 promotes the progression of cholangiocarcinoma by maintaining DNA hypermethylation of PLA2G2A	35
Examining the evidence for mutual modulation between m6A modification and circular RNAs: current knowledge and future prospects	35
Ginseng-derived nanoparticles reprogram macrophages to regulate arginase-1 release for ameliorating T cell exhaustion in tumor microenvironment	35
Transfection with Plasmid-Encoding lncRNA-SLERCC nanoparticle-mediated delivery suppressed tumor progression in renal cell carcinoma	35
Galectin-3 induces pathogenic immunosuppressive macrophages through interaction with TREM2 in lung cancer	35
DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity	35
AGD1/USP10/METTL13 complexes enhance cancer stem cells proliferation and diminish the therapeutic effect of docetaxel via CD44 m6A modification in castration resistant prostate cancer	35
Flavokawain A is a natural inhibitor of PRMT5 in bladder cancer	35
Flap endonuclease 1 and DNA-PKcs synergistically participate in stabilizing replication fork to encounter replication stress in glioma cells	35
Involvement of lncRNAs in cancer cells migration, invasion and metastasis: cytoskeleton and ECM crosstalk	34
Colorectal carcinoma peritoneal metastases-derived organoids: results and perspective of a model for tailoring hyperthermic intraperitoneal chemotherapy from bench-to-bedside	34
LINC00240 in the 6p22.1 risk locus promotes gastric cancer progression through USP10-mediated DDX21 stabilization	34
Synergistic intravesical instillation for bladder cancer: CRISPR-Cas13a and fenbendazole combination therapy	34
VSIG4+ tumor-associated macrophages mediate neutrophil infiltration and impair antigen-specific immunity in aggressive cancers through epigenetic regulation of SPP1	34
Amino acid metabolism reprogramming: shedding new light on T cell anti-tumor immunity	34
Unveiling the role of osteosarcoma-derived secretome in premetastatic lung remodelling	34
A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma	34
Preoperative liquid biopsy transcriptomic panel for risk assessment of lymph node metastasis in T1 gastric cancer	34
The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promising circulating biomarkers	33
Extracellular vesicle digital scoring assay for assessment of treatment responses in hepatocellular carcinoma patients	33
Correction: Integrin-linked kinase-frizzled 7 interaction maintains cancer stem cells to drive platinum resistance in ovarian cancer	33
Correction to: LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells	33
Correction: Loss of LKB1 disrupts breast epithelial cell polarity and promotes breast cancer metastasis and invasion	33
Correction: PSMD9 promotes the malignant progression of hepatocellular carcinoma by interacting with c-Cbl to activate EGFR signaling and recycling	33
Correction: Inhibition of MTA1 by ERα contributes to protection hepatocellular carcinoma from tumor proliferation and metastasis	33
Sushi domain-containing protein 4 binds to epithelial growth factor receptor and initiates autophagy in an EGFR phosphorylation independent manner	33
Correction: JMJD2C promotes colorectal cancer metastasis via regulating histone methylation of MALAT1 promoter and enhancing β-catenin signaling pathway	33
Correction: The epigenetic downregulation of LncGHRLOS mediated by RNA m6A methylase ZCCHC4 promotes colorectal cancer tumorigenesis	33
Expression and activation of nuclear hormone receptors result in neuronal differentiation and favorable prognosis in neuroblastoma	32
From ductal carcinoma in situ to invasive breast cancer: the prognostic value of the extracellular microenvironment	32
Baseline levels and dynamic changes of cfDNA, tumor fraction and mutations to anticipate the clinical course of small cell lung cancer (SCLC) patients treated with first-line atezolizumab and chemothe	32
Direct interaction of TrkA/CD44v3 is essential for NGF-promoted aggressiveness of breast cancer cells	31
DCAF1 interacts with PARD3 to promote hepatocellular carcinoma progression and metastasis by activating the Akt signaling pathway	31
Immune checkpoints are predominantly co-expressed by clonally expanded CD4+FoxP3+ intratumoral T-cells in primary human cancers	31
HES1-mediated down-regulation of miR-138 sustains NOTCH1 activation and promotes proliferation and invasion in renal cell carcinoma	31
An IgE antibody targeting HER2 identified by clonal selection restricts breast cancer growth via immune-stimulating activities	31
Partial p53 reactivation is sufficient to induce cancer regression	31